



Barbarot, S., Rogers, N. K., Abuabara, K., Aubert, H., Chalmers, J., Flohr, C., Hanifin, J., Naldi, L., Margolis, D. J., Paul, C., Ridd, M. J., Anna Schuttelaar, M-L., Simpson, E., Tauber, M., Volke, A., Weidinger, S., Wilkes, S. R., Wollenberg, A., & Thomas, K. S. (2016). Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review. *Journal of the American Academy of Dermatology*, 75(5), 1038-1044.
<https://doi.org/10.1016/j.jaad.2016.05.043>

Peer reviewed version

Link to published version (if available):
[10.1016/j.jaad.2016.05.043](https://doi.org/10.1016/j.jaad.2016.05.043)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at <http://www.sciencedirect.com/science/article/pii/S0190962216303255>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Strategies for measuring long-term control in atopic dermatitis trials: a systematic review

Authors: Sebastien Barbarot PhD^{1,2}, Natasha K Rogers PhD¹, Katrina Abuabara MD³, Helene Aubert MD², Joanne Chalmers PhD¹, Carsten Flohr PhD⁴, Jon Hanifin⁵, Luigi Naldi MD⁶, David J Margolis MD⁷, Carle Paul MD⁸, Matthew J Ridd PhD⁹, Marie-Louise Anna Schuttelaar PhD¹⁰, Eric Simpson MD⁵, Marie Tauber MD⁸, Annika Volke MD¹¹, Stephan Weidinger MD¹², Sally R Wilkes PhD¹, Andreas Wollenberg PhD¹³, Kim S Thomas PhD¹

¹Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK

²Department of Dermatology, CHU de Nantes, Nantes, France.

³Department of Dermatology, University of California San Francisco, USA

⁴Population-Based Dermatology Research Unit, St John's Institute of Dermatology, Guy's & St Thomas' NHS Foundation Trust and King's College London, London, UK

⁵Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA

⁶Study Centre Italian Group for Epidemiologic Research in Dermatology (GISED) and Department of Dermatology, Azienda Ospedaliera papa Giovanni XXIII, Bergamo, Italy

⁷Department of Dermatology, Department of Biostatistics and Epidemiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA

⁸Dermatology, Paul Sabatier University and Hopital Larrey, Toulouse, France

⁹School of Social & Community Medicine, University of Bristol, Bristol, UK

¹⁰Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

¹¹Department of Dermatology, University of Tartu, Tartu, Estonia

¹²Department of Dermatology, Venereology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Germany

¹³Department of Dermatology and Allergy, Ludwig-Maximilian University Munich, Germany

***Corresponding author:** Professor Kim Thomas, The University of Nottingham, King's Meadow Campus, Lenton Lane Nottingham, NG7 2NR (kim.thomas@nottingham.ac.uk)

Reprint requests: See above

Funding: MJR is funded by National Institute for Health Research (NIHR) Post Doctoral Fellowship (PDF-2014-07-013) and the views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

Conflicts of interest: None. This review has been conducted in support of the Harmonizing Outcome Measure for Eczema (HOME) initiative.

Word Count:

Abstract: 200

Capsule summary:47

Text: 2498

Figure: 3

Tables: 2

IRB review – not required – secondary data synthesis

Key words: atopic eczema, atopic dermatitis, long-term control, outcome measures, RCTs, systematic review; flares.

- There is no consensus over how best to measure long-term control of atopic dermatitis in clinical trials
- To date, repeated measurement of eczema severity, assessment of flares and use of atopic dermatitis medications have all been used.
- Consensus agreement of core outcome sets for atopic dermatitis will improve evidence-based practice.

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease. There are no standardised methods for capturing long-term control of AD.

Objective: To identify how long-term control has been captured in published randomised controlled trials (RCTs). Results will initiate consensus discussions on how best to measure long-term control in the core outcome set for AD.

Methods: Systematic review of RCTs of AD treatments published between 2000 and 2013, with a follow-up period of ≥ 3 months, at least one outcome measure recorded at ≥ 3 time-points, full paper available, and published in English.

Results: 101/ 353 RCTs were eligible. Methods to capture long-term control included: repeated measurement of AD outcomes (92 RCTs; 91%), use of AD medication (29 RCTs; 28.7%); and AD flares/remissions (26 RCTs; 25.7%).

Repeated measurements of AD outcomes were typically collected 3 to 5 times during a trial, but analysis methods often failed to make best use of the data. Time to first flare was most commonly for trials including flare data (21/52).

Medication-use was recorded based on quantity, potency and frequency of application.

Limitations: Included RCT data only

Conclusion: This review illustrates the difficulties in measuring long-term control, and points to the need for improved harmonization of outcomes.

16 **Abbreviations**

17 AD, Atopic Dermatitis

18 ANOVA, Analysis of Variance

19 ANCOVA, Analysis of Covariance

20 BSA, Body Surface Area

21 EASI, Eczema Area and Severity Index)

22 IGA, Investigators Global Assessment

23 HOME, Harmonizing Outcome Measure for Eczema

24 POEM, Patient-Oriented Eczema Measure

25 RTC, Randomised Controlled Trial

26

27

INTRODUCTION

Atopic dermatitis (syn. atopic eczema) is a highly prevalent, itchy, inflammatory skin condition that affects children and adults. As with other chronic inflammatory diseases, AD severity tends to wax and wane over time, with periods of relative remission, interspersed with periods of increased disease activity or “flare”.¹ AD treatments aim to reduce disease intensity and minimise the number of flares and increase the duration of remissions. The ability to measure long-term control of AD over time is an important outcome when evaluating effectiveness of treatments, as this reflects patients’ experiences of living with the condition, and long term control has been identified as a core outcome to be included in future AD clinical trials².

To date, there is little consensus over how best to capture long-term control in AD. Two systematic reviews have demonstrated the variability in AD flare definitions used in published studies,^{3,4} and have highlighted the methodological challenges in capturing AD flares. Other approaches to capture long-term control include measurement of anti-inflammatory medication-use over time, or the repeated measurement of AD severity and other health outcomes.

The Harmonizing Outcome Measure for Eczema (HOME) initiative (www.homeforeczema.org) identified long-term control as one of four key domains to measure in all clinical trials in AD. The current systematic review has been conducted in order to inform the HOME initiative’s consensus discussions on how long-term control has been captured in previously published randomized controlled trials (RCTs). It represents stage 1 on the HOME Roadmap⁵ namely to identify available outcome instruments for capturing the domain of interest.

METHODS

This systematic review was performed according to PRISMA recommendations⁶. The protocol was agreed prior to starting the review, and registered online (October 6, 2014) (<http://nottingham.ac.uk/research/groups/cebd/documents/researchdocs/ltc-protocol-final.pdf>).

Eligibility criteria and search strategy

We searched for RCTs with at least a 3-month follow-up period⁷ that included adults or children with AD, and which were published between January 1, 2000 and March 12, 2013. This period was chosen as prior to 2000, most AE trials were of relatively short duration.⁸ Eligible studies were identified using the Global Resource of Eczema Trials (GREAT) database (www.greatdatabase.org.uk). This freely available online database contains

records of RCTs for AD treatments found within MEDLINE, EMBASE, CINHAL, AMED, LILACS, the Cochrane Library and the Skin Group Specialised Register databases.

The search strategy used to identify RCTs in the GREAT database and validation of the GREAT database have been published elsewhere.⁹ Observational studies were not included in this review due to time and resource limitations.

Study selection and data extraction

Inclusion criteria were predefined. Studies were included if the duration of patient follow-up was ≥ 3 months, and a clinician or patient-reported outcome measure was recorded at three or more time points. We excluded studies that were published in abstract form only, those which did not include clinical outcomes (e.g. studies only containing data pertaining to biomarkers or skin barrier function tests), and those that were not published in English. Titles of studies were retrieved and the full-text was then obtained and screened against the inclusion criteria by two authors (NR, SB). Responses were compared and discrepancies resolved by consensus (NR, SB).

Studies which met the inclusion criteria were divided between author pairs, who independently extracted data using a standardised data extraction form. Details were extracted for: (i) trial attributes (size of trial, age of participants); (ii) repeated measurement of clinician or patient-reported AD outcomes over time (iii) use of AD medication - defined as any treatment used to control AD symptoms other than the randomly allocated intervention; (iv) AD flares / relapse - defined as a decline in condition (worsening of symptoms) which met one of the recommended descriptions of flare³, regardless of whether 'flare', 'relapse' or 'remission' was specifically used within the text. For all long-term control outcomes, details of how the outcomes were recorded, analysed and presented in the paper were recorded. Data extraction forms were reviewed by another two authors (NR, SW), who checked for completeness and resolved any discrepancies by referring to the original trial publications.

Results were summarised qualitatively, and the statistical techniques used in the original trial reports were reviewed by a medical statistician to ascertain the appropriateness of the analysis techniques used. The

analyses techniques described in the trial reports were categorised into “efficient analysis techniques” (best use of all available data); “inefficient analysis techniques” (statistically correct, but potentially inefficient use of available data); “inappropriate analysis techniques” (analysis of multiple time points individually without adjustment for multiple testing); or “unclear”.

RESULTS

A search of the GREAT database for studies published between 1 January 2000 and 12 March 2013 yielded a total of 353 RCTs (Fig1 and Appendix). Overall, 101 trials were included in the review (67% included either children or adults, 31% included both children and adults, one trial did not state the ages of the participants involved). Nearly all trials were conducted in a secondary or tertiary care setting.

Types of long-term control outcomes used

Long-term control outcomes were measured in a variety of ways, and 72 (71.2%) trials measured long-term control in two or more ways. In 92 trials (91%) repeated measurements of clinical or patient-reported outcomes were reported, in 26 trials (25.7%) AD flares were captured as an outcome measure, and in 29 trials (28.7%) the use of AD medication was used to measure long-term control. In all cases there was considerable heterogeneity in how the outcomes were defined and captured.

Of the studies assessed, 68/101 (67.3%) had at least one graphical representation of long term data.

Repeated measurement of AE outcomes

A total of 196 outcomes were used in the 92 trials that reported repeated measurement of AD outcomes (median 1.9 per trial) (Figure 2). The most commonly used outcomes were: SCORAD or objective SCORAD (25%), quality of life scales (14%), pruritus scales (10%), Body Surface Area (BSA) (8%), EASI or modified EASI (8%) and Investigator Global Assessment (IGA) (7%). As previously shown, there was large variability in IGA definitions between studies¹⁰. The breakdown of clinician-reported and patient-reported outcomes is summarised in Figure 3.

Outcomes were most often collected on a monthly basis (40% monthly, 27% more than a month apart, 25% irregular intervals, 6% weekly, 0.5% daily). Most trials (66/92, 71%) collected the outcomes between 3 and 5 times over the duration of the trial, with 11 trials including 11 or more data collection points.

Medication use

The use of AD medications as an indicator of disease control (rather than adherence with study medications), was collected by less than a third of included trials (29/101), and only four reported this information as a primary outcome. Topical corticosteroid use was assessed in all 29 of these trials, but some trials also monitored other types of medication, including: antibiotics (n = 5); antihistamines (n = 5); calcineurin inhibitors (n = 4); emollients (n = 2); and systemic therapy (n = 2). Information was documented solely during visits for just over half of the studies (15/29, 52%), with a minority collecting data on medication use from participant diaries (4/29, 14%), or a combination of clinic visits and participant diaries (3/29, 10%). The remaining studies did not give any details about the collection method (7/29, 24%). None of the included trials that provided details of data collection gathered information from medical notes. The manner in which medication use was captured varied considerably and included measurement of frequency of application, amount of medication used and potency (Figure 4).

AD flares

For 26/101 (25%) included trials, the concept of disease flares (including relapse / remission) was captured, and for 15 (58%) of these, flare outcomes were the primary outcome. In line with previously suggested categorisations for flare outcomes³, 9/26 (35%) used an arbitrary cut-off such as a change in score from a

baseline measurement (e.g IGA>4 or SCORAD>75% of baseline) , 6/26 (23%) used a behavioural measure such as the need for stepping-up topical steroid treatment (rescue medication) according to the patient or the physician, 9/26 (35%) used a composite measure (e.g IGA>4 AND the need for rescue medication), and 2/26 (7%) were classed as other/unknown. Data on flares was most commonly collected during clinic visits (14/26, 53%), with only 6/26 (23%) being collected from participants at home.

Most trials analysed flares in multiple ways, with a total 52 analyses performed (Table 1). Time to first flare was the most commonly used summary measure (21/52 analyses), followed by number of flares (17/52 analyses).

Data analysis techniques used

Despite considerable efforts having been taken to collect long-term control outcome data throughout these trials, only 72/196 (37%) of the reported analyses made best use of the available data and included all time points in the analysis (Table 2). Analyses that were considered to be best use of the data included: ANOVA (n = 35 analyses), linear mixed model (n=13 analyses), ANCOVA (n=12 analyses), nonlinear mixed model (n=2 analyses), non-parametric repeated measures (n=2 analyses), area under the curve (n=1 analysis), log-rank test (n=1 analysis), McNemar (n=1 analysis), other (n=5 analyses).

DISCUSSION

Main findings

This review shows how previous researchers have tackled the measurement of long-term control in published RCTs of AD treatments, and serves to highlight some of the complexities of measuring disease control over time.

Since almost all of the trials used repeated measurement of clinician or patient-reported outcomes over time, it would appear that such an approach is both feasible and acceptable. However, appropriate analysis of these data is challenging, and few trials reported their results in the most appropriate and efficient manner. The analysis of repeated measures requires the use of specific statistical tests (such as ANOVA, ANCOVA or mixed models). Using multiple tests to compare data between groups at each time points leads to increased risk of identifying a significant difference by chance. The fact that 39.7% of the reported analyses described in this review were performed using inappropriate statistical techniques, such as repeated significance testing at multiple time points (without adjustment for multiple testing),¹¹ is something that the dermatology research community and academic journals could do more to address.

We chose to report medication usage and analysis of flares separately. However, these concepts are often linked, as incidence of flares may be inversely related to the amount of anti-inflammatory medication used, and flare definitions commonly rely on the concept of escalation of therapy as an indicator of worsening disease.¹² Similarly, worsening disease severity as captured by validated severity scales used repeatedly over time are likely to be capturing disease flares as experienced at specific time points. Further work is required to establish whether choosing one option over another is likely to miss a fundamental aspect of disease control that is important to patients.

In considering the suitability of different methods for capturing long-term control, several issues are relevant. The need for chosen outcomes to be feasible in all trial settings is crucial when selecting measurement instruments for a core outcome set, and this can be a particular challenge when evaluating long-term control, which can be resource intensive and difficult to interpret.¹²

Equally important is the concept that outcomes should be relevant to patients with all severities of disease and healthcare settings. Most AD patients are treated in primary care and have relatively mild disease. As such, many patients are controlled with emollients only and rarely experience severe flares. In this setting, judging treatment response based on the amount of topical corticosteroid used, or the number of flares experienced over periods of a few months is unlikely to be an efficient trial design due to low event rates. Similarly, for patients with very severe disease who require systemic medication, or who experience fewer fluctuations in their disease severity, the concept of disease flares defined by topical corticosteroid use or flares may be less useful.

The optimum frequency of outcome assessments (e.g. daily, weekly, monthly or bi-monthly) has yet to be established, and will no doubt be determined by the feasibility of outcome assessments. For patient-reported outcomes, more frequent data collection may be possible through the use of ‘apps’ or other on-line data collection tools¹³, thus facilitating data collection between clinic visits. By contrast, long-term control measured by independent observers during clinic visits or at participants’ homes, will by necessity limit the number and timing of outcome assessments.

As a chronic, relapsing condition, AD has many similarities with other inflammatory conditions such as asthma and rheumatoid arthritis, where considerable efforts are now being made to establish working definitions for disease flares.¹⁴⁻¹⁷ An agreed definition of disease flare (or remission), as part of the outcome domain for long-term control would be a helpful step forward, and consistency in assessing AD long term control in RCTs and observational studies will improve the comparability of research, thus benefitting patients and health care providers. It is also salutatory that over half of the identified trials had to be excluded from this review as they were of less than 3 months’ duration, making assessment of long-term control impossible.

Strengths and limitations

This review sought to summarise the current approaches used in previously published AD RCTs to capture long-term control of AD. However, this approach means that more recent trends in data collection may have been missed as the included trials will all have been conceived and designed several years ago. Similarly, by excluding observational studies, it is possible that alternative means of capturing long-term control of AD have

been missed. This review was also unable to comment directly on the feasibility of different approaches, or on the practical difficulties encountered from the methods used.

What does this mean for the HOME initiative and for future research

This systematic review has been conducted on behalf of the Long-Term Control Working Group for the HOME initiative and represents the first step in defining how best to measure long-term control in clinical trials as part of the core outcome set for AD. A review of validation studies that have evaluated outcomes for long-term control will be conducted, along with a suite of studies to address known research gaps, including validity and responsiveness of different approaches to capturing long-term control, and the optimum timing of outcome assessments.

The HOME initiative has already achieved international consensus that clinical signs should be captured using the Eczema Area and Severity Index (EASI)^{7, 18} and that patient-reported symptoms should be captured using the Patient Oriented Eczema Measure (POEM). As such, in the absence of an agreed instrument for capturing long-term control, we recommend an ‘interim solution’ of using at least one of these scales at multiple time points (preferably at least monthly for a minimum of 3 months). The analysis of the data should be done using appropriate statistical techniques that take into account all time points in a single analysis. If possible, it would be ideal to use the HOME core outcome instruments for signs and symptoms alongside measures of disease flare or topical medication use, as this would provide additional data to inform future consensus agreement over the best way to measure long-term control.

Acknowledgements

This study has been conducted in support of the Harmonizing Outcome Measure for Eczema (HOME) initiative, and we thank HOME members who have helped to inform the development and concepts described in this study. For full details of the HOME initiative see: www.homeforeczema.org

Table Legends

Table 1: Summary of methods to analyse flare outcomes

Table 2: Summary of methods of analysis for repeated measures data

FIGURE LEGENDS

Figure 1: LTC Flow diagram

Figure 2: Distribution of the 196 outcomes used in 92 trials that reported repeated measurement of AD outcomes

Figure 3: Number of patient-reported and clinician-reported outcomes used in the included trials

Figure 4: Methods of collection for medication use

APPENDIX

List of included studies

REFERENCES

1. Weidinger S , Novak N. Atopic dermatitis. *Lancet* (London, England) 2015.
2. Schmitt J, Spuls P, Boers M, Thomas K, Chalmers J, Roekevisch E et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. *Allergy* 2012;67:1111-7.
3. Langan SM, Schmitt J, Williams HC, Smith S , Thomas KS. How are eczema 'flares' defined? A systematic review and recommendation for future studies. *The British journal of dermatology* 2014;170:548-56.
4. Langan SM, Silcocks P , Williams HC. What causes flares of eczema in children? *Br J Dermatol* 2009;161:640-6.
5. Schmitt J, Apfelbacher C, Spuls PI, Thomas KS, Simpson EL, Furue M et al. The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. *J Invest Dermatol* 2015;135:24-30.
6. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*, 2009;339:b2700.
7. Chalmers JR, Schmitt J, Apfelbacher C, Dohil M, Eichenfield LF, Simpson EL et al. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). *The British journal of dermatology* 2014;171:1318-25.
8. Hoare C, Li Wan Po A , Williams H. Systematic review of treatments for atopic eczema. *Health technology assessment* 2000;4:1-191.
9. Nankervis H, Maplethorpe A , Williams HC. Mapping randomized controlled trials of treatments for eczema--the GREAT database (the Global Resource of Eczema Trials: a collection of key data on randomized controlled trials of treatments for eczema from 2000 to 2010). *BMC dermatology* 2011;11:10.
10. Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC , Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. *J Am Acad Dermatol* 2016;74:288-94.
11. Matthews JN, Altman DG, Campbell MJ , Royston P. Analysis of serial measurements in medical research. *BMJ (Clinical research ed)* 1990;300:230-5.


12. Thomas KS, Stuart B, O'Leary CJ, Schmitt J, Paul C, Williams HC et al. Validation of treatment escalation as a definition of atopic eczema flares. *PLoS One* 2015;10:e0124770.
13. Snyder CF, Aaronson NK, Choucair AK, Elliott TE, Greenhalgh J, Halyard MY et al. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation* 2012;21:1305-14.
14. Bartlett SJ, Hewlett S, Bingham CO, 3rd, Woodworth TG, Alten R, Pohl C et al. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. *Ann Rheum Dis* 2012;71:1855-60.
15. van der Maas A , den Broeder AA. Measuring flares in rheumatoid arthritis. (Why) do we need validated criteria? *J Rheumatol* 2014;41:189-91.
16. Bartlett SJ, Bykerk VP, Cooksey R, Choy EH, Alten R, Christensen R et al. Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary. *J Rheumatol* 2015;42:2185-9.
17. Loymans RJ, Ter Riet G , Sterk PJ. Definitions of asthma exacerbations. *Current opinion in allergy and clinical immunology* 2011;11:181-6.
18. Schmitt J, Spuls PI, Thomas KS, Simpson E, Furue M, Deckert S et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. *J Allergy Clin Immunol* 2014;134:800-7.


Analysis	Number
Time to first flare	21
Number of flares	17
Duration of remission	5
Duration of flare	4
“Totally controlled weeks” and “well controlled weeks”	1
Other	4

Appropriateness of analysis	Category	Number (%)
Best use of data	Took into account all time points in single analysis	73 (37.2)
Inefficient analysis	Only compared baseline and end point	30 (15.3)
Inefficient analysis	Only data at a single time point is assessed	4 (2.0)
Inappropriate analysis	Compared each time point to baseline individually	71 (36.2)
Inappropriate analysis	Compared groups at each individual time point	7 (3.5)
Not analysable	Unclear	11 (5.6)

Figure 1: LTC Flow diagram

*Multiple categories are possible





- BSA (Body Surface Area)
- EASI
- Global Assessment (Investigator)
- Global Assessment (Patient)
- Other
- Pruritus
- Pruritus and sleep
- Quality of Life
- SASSAD
- SCORAD
- Sleep




Figure 2: Number of patient-reported and clinician-reported outcomes used in the included trials




Figure 3: Methods of collection for medication use

APPENDIX

Publications meeting inclusion criteria

1. Alex P, Payne A, Desai A, Centola M, Yesudas T. HAT-01, a novel herbal preparation, is superior to corticosteroids and pimecrolimus for the treatment of moderate to severe atopic dermatitis. *Journal of the American Academy of Dermatology*. 2013;68(4, Supplement 1):AB76.
2. Arkwright PD, David TJ. Effect of *Mycobacterium vaccae* on atopic dermatitis in children of different ages. *Br J Dermatol*. 2003;149(5):1029-34.
3. Arkwright PD, David TJ. Intradermal administration of a killed *Mycobacterium vaccae* suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. *J Allergy Clin Immunol*. 2001;107(3):531-4.
4. Back O, Bartosik J. Systemic ketoconazole for yeast allergic patients with atopic dermatitis. *J Eur Acad Dermatol Venereol*. 2001;15(1):34-8.
5. Beck LA, Thaci D, Hamilton JD, et al. Systemic treatment of patients with severe atopic dermatitis (AD) with an anti IL-4R alpha mAb (REGN668/SAR231893) results in rapid and sustained improvements in disease signs and symptoms. *J Invest Dermatol*. 2013;133 (Suppl):p. S178.
6. Bermanian MH, Movahedi M, Farhoudi A, et al. High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis. *Iran J Allergy Asthma Immunol*. 2005;4(3):139-43.
7. Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. *Br J Dermatol*. 2002;147(2):324-30.
8. Berth-Jones J, Arkwright PD, Marasovic D, et al. Killed *Mycobacterium vaccae* suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. *Clin Exp Allergy*. 2006;36(9):1115-21.
9. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. *BMJ*. 2003;326(7403):1367.
10. Bostoen J, Geusens B, Bracke S, Dekeyser S, Lambert J. Follow-up on the effect of a patient educational programme: early results of a prospective randomized controlled trial in psoriasis and atopic dermatitis. *Br J Dermatol*. 2011;165:e34-5.
11. Breneman D, Fleischer AB, Jr., Abramovits W, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. *J Am Acad Dermatol*. 2008;58(6):990-9.
12. Brenninkmeijer EE, Spuls PI, Lindeboom R, van der Wal AC, Bos JD, Wolkerstorfer A. Excimer laser vs. clobetasol propionate 0.05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot. *Br J Dermatol*. 2010;163(4):823-31.
13. Brothers S, Asher MI, Jaksic M, Stewart AW. Effect of a *Mycobacterium vaccae* derivative on paediatric atopic dermatitis: a randomized, controlled trial. *Clin Exp Dermatol*. 2009;34(7):770-5.
14. Brouwer ML, Wolt-Plompen SA, Dubois AE, et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. *Clin Exp Allergy*. 2006;36(7):899-906.
15. Byremo G, Rod G, Carlsen KH. Effect of climatic change in children with atopic eczema. *Allergy*. 2006;61(12):1403-10.
16. Callaway J, Schwab U, Harvima I, et al. Efficacy of dietary hempseed oil in patients with atopic dermatitis. *J Dermatolog Treat*. 2005;16(2):87-94.

17. Cheng HM, Chiang LC, Jan YM, Chen GW, Li TC. The efficacy and safety of a Chinese herbal product (Xiao-Feng-San) for the treatment of refractory atopic dermatitis: a randomized, double-blind, placebo-controlled trial. *Int Arch Allergy Immunol.* 2011;155(2):141-8.
18. Chinn DJ, Poyner T, Sibley G. Randomized controlled trial of a single dermatology nurse consultation in primary care on the quality of life of children with atopic eczema. *Br J Dermatol.* 2002;146(3):432-9.
19. Chung BY, Kim HO, Kim JH, Cho SI, Lee CH, Park CW. The proactive treatment of atopic dermatitis with tacrolimus ointment in Korean patients: a comparative study between once-weekly and thrice-weekly applications. *Br J Dermatol.* 2013;168(4):908-10.
20. Cukrowska B, Ceregra A, Rosiak I, et al. The influence of probiotic *Lactobacillus casei* and *paracasei* strains on clinical status of atopic eczema in children with food allergy on cow's milk proteins. [Polish]. *Pediatrica Wspolczesna.* 2008;10(2):67-70.
21. Czech W, Brautigam M, Weidinger G, Schopf E. A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. *J Am Acad Dermatol.* 2000;42(4):653-9.
22. Diepgen TL. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. *Pediatr Allergy Immunol.* 2002;13(4):278-86.
23. Drago L, Iemoli E, Rodighiero V, Nicola L, De Vecchi E, Piconi S. Effects of *Lactobacillus salivarius* LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study. *Int J Immunopathol Pharmacol.* 2011;24(4):1037-48.
24. Eichenfield LF. A randomized, double-blind, placebo-controlled, parallel group study of nanocrystalline silver (NPI 32101) cream in pediatric atopic dermatitis (AD). *Journal of the American Academy of Dermatology.* 2007;56(2):AB75.
25. El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. *Eur J Pediatr.* 2013;172(3):351-6.
26. Farina S, Gisondi P, Zanoni M, et al. Balneotherapy for atopic dermatitis in children at Comano spa in Trentino, Italy. *J Dermatolog Treat.* 2011;22(6):366-71.
27. Futamura M, Masuko I, Hayashi K, Ohya Y, Ito K. Effects of a short-term parental education program on childhood atopic dermatitis: a randomized controlled trial. *Pediatr Dermatol.* 2013;30(4):438-43.
28. Ghanei N, Siassi F, Zandieh F, Rahimi A. Effectiveness of prebiotic in atopic dermatitis reduction in 7-24 months old children living in Isfahan. [Arabic]. *Journal of Isfahan Medical School.* 2011;28(113):679-87.
29. Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, Mulder PG, Oranje AP. Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? *Pediatr Allergy Immunol.* 2009;20(1):59-66.
30. Gollnick H, Kaufmann R, Stough D, et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. *Br J Dermatol.* 2008;158(5):1083-93.
31. Gore C, Custovic A, Tannock GW, et al. Treatment and secondary prevention effects of the probiotics *Lactobacillus paracasei* or *Bifidobacterium lactis* on early infant eczema: randomized controlled trial with follow-up until age 3 years. *Clin Exp Allergy.* 2012;42(1):112-22.
32. Granlund H, Erkkö P, Remitz A, et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. *Acta Derm Venereol.* 2001;81(1):22-7.
33. Grillo M, Gassner L, Marshman G, Dunn S, Hudson P. Pediatric atopic eczema: the impact of an educational intervention. *Pediatr Dermatol.* 2006;23(5):428-36.
34. Gruber C, Wendt M, Sulser C, et al. Randomized, placebo-controlled trial of *Lactobacillus rhamnosus* GG as treatment of atopic dermatitis in infancy. *Allergy.* 2007;62(11):1270-6.

35. Gutgesell C, Heise S, Seubert S, et al. Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis. *Br J Dermatol*. 2001;145(1):70-4.
36. Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. *J Am Acad Dermatol*. 2011;64(6):1074-84.
37. Han Y, Kim B, Ban J, et al. A randomized trial of *Lactobacillus plantarum* CJLP133 for the treatment of atopic dermatitis. *Pediatr Allergy Immunol*. 2012;23(7):667-73.
38. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. *Br J Dermatol*. 2002;147(3):528-37.
39. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. *J Am Acad Dermatol*. 2001;44(1 Suppl):S28-38.
40. Harper JL, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. *Br J Dermatol*. 2000;142(1):52-8.
41. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. *J Dtsch Dermatol Ges*. 2010;8(12):990-8.
42. Heinlin J, Schiffner-Rohe J, Schiffner R, et al. A first prospective randomized controlled trial on the efficacy and safety of synchronous balneophototherapy vs. narrow-band UVB monotherapy for atopic dermatitis. *J Eur Acad Dermatol Venereol*. 2011;25(7):765-73.
43. Hennino A, Cornu C, Rozieres A, et al. Influence of measles vaccination on the progression of atopic dermatitis in infants. *Pediatr Allergy Immunol*. 2007;18(5):385-90.
44. Hon KL, Leung TF, Ng PC, et al. Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis: a randomized, double-blind, placebo-controlled study. *Br J Dermatol*. 2007;157(2):357-63.
45. Hon KL, Leung TF, Ng PC, et al. Therapeutic effect and safety of a traditional Chinese medicine for atopic dermatitis in children: a randomised, double-blind, placebo-controlled study. *Hong Kong Med J*. 2011;17 Suppl 2:38-40.
46. Huang JT, Abrams M, Tloughan B, Rademaker A, Paller AS. Treatment of *Staphylococcus aureus* colonization in atopic dermatitis decreases disease severity. *Pediatrics*. 2009;123(5):e808-14.
47. Iemoli E, Trabattoni D, Parisotto S, et al. Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. *J Clin Gastroenterol*. 2012;46 Suppl:S33-40.
48. Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. *Clin Exp Allergy*. 2000;30(11):1604-10.
49. Jang IG, Yang JK, Lee HJ, et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. *J Am Acad Dermatol*. 2000;42(6):1033-40.
50. Jee SJ, Kim JH, Baek HS, Lee HB, Oh JW. Long-term Efficacy of Intravenous Immunoglobulin Therapy for Moderate to Severe Childhood Atopic Dermatitis. *Allergy Asthma Immunol Res*. 2011;3(2):89-95.
51. Jin YY, Cao RM, Chen J, et al. Partially hydrolyzed cow's milk formula has a therapeutic effect on the infants with mild to moderate atopic dermatitis: a randomized, double-blind study. *Pediatr Allergy Immunol*. 2011;22(7):688-94.
52. Kirkup ME, Birchall NM, Weinberg EG, Helm K, Kennedy CT. Acute and maintenance treatment of atopic dermatitis in children - two comparative studies with fluticasone propionate (0.05%) cream. *J Dermatolog Treat*. 2003;14(3):141-8.
53. Kobayashi H, Ishii M, Takeuchi S, et al. Efficacy and Safety of a Traditional Herbal Medicine, Hochu-ekki-to in the Long-term Management of Kikyo (Delicate Constitution) Patients with Atopic Dermatitis: A 6-month, Multicenter, Double-blind, Randomized, Placebo-controlled Study. *Evid Based Complement Alternat Med*. 2010;7(3):367-73.

54. Koch C, Dolle S, Metzger M, et al. Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial. *Br J Dermatol*. 2008;158(4):786-92.
55. Koller DY, Halmerbauer G, Bock A, Engstler G. Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3-month trial. *Pediatr Allergy Immunol*. 2007;18(4):335-8.
56. Kuznecovs I, Jegina K, Kuznecovs S. Atovastatin and polyphenol effect on atopic dermatitis: pathogenesis links in adult patients. *Allergy*. 2010;65(s92):75.
57. Kwon HB, Ahn BJ, Choi Y, et al. Combination of glucosamine improved therapeutic effect of low-dose cyclosporin A in patients with atopic dermatitis: a pilot study. *J Dermatol*. 2013;40(3):207-10.
58. Luger TA, Lahfa M, Folster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. *J Dermatolog Treat*. 2004;15(3):169-78.
59. Majoie IM, Oldhoff JM, van Weelden H, et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. *J Am Acad Dermatol*. 2009;60(1):77-84.
60. Mandelin J, Remitz A, Virtanen H, Reitamo S. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double-blind, comparative trial. *Acta Derm Venereol*. 2010;90(2):170-4.
61. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. *Lancet*. 2006;367(9513):839-46.
62. Meurer M, Eichenfield LF, Ho V, Potter PC, Werfel T, Hultsch T. Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomized, double-blind trial. *J Dermatolog Treat*. 2010;21(3):157-66.
63. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. *Dermatology*. 2002;205(3):271-7.
64. Moroi M, Uchi S, Nakamura K, et al. Beneficial effect of a diet containing heat-killed *Lactobacillus paracasei* K71 on adult type atopic dermatitis. *J Dermatol*. 2011;38(2):131-9.
65. Namazova-Baranova L, Vishneva E., Levina J., et al. Combined therapy of atopic dermatitis in children. *Allergy*. 2012 (67):181-2.
66. Nermes M, Kantele JM, Atosuo TJ, Salminen S, Isolauri E. Interaction of orally administered *Lactobacillus rhamnosus* GG with skin and gut microbiota and humoral immunity in infants with atopic dermatitis. *Clin Exp Allergy*. 2011;41(3):370-7.
67. Neumann E, Amtage D, Bruckner-Tuderman L, Mockenhaupt M. A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis. *J Dtsch Dermatol Ges*. 2008;6(7):548-53.
68. Nieto A, For P. Efficacy and safety of pimecrolimus cream 1% in infants with mild-to-moderate atopic dermatitis: A randomised 5-year study. *Allergy*. 2012;67(Suppl. 96):16-7.
69. Novak N, Bieber T, Hoffmann M, et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. *J Allergy Clin Immunol*. 2012;130(4):925-31 e4.
70. Oosting AJ, de Bruin-Weller MS, Terreehorst I, et al. Effect of mattress encasings on atopic dermatitis outcome measures in a double-blind, placebo-controlled study: the Dutch mite avoidance study. *J Allergy Clin Immunol*. 2002;110(3):500-6.
71. Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. *J Allergy Clin Immunol*. 2007;120(1):164-70.
72. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. *J Am Acad Dermatol*. 2001;44(1 Suppl):S47-57.

73. Passeron T, Lacour JP, Fontas E, Ortonne JP. Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years. *Allergy*. 2006;61(4):431-7.
74. Paul C, Lahfa M, Bachelez H, Chevrete S, Dubertret L. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. *Br J Dermatol*. 2002;147(3):518-22.
75. Peserico A, Stadtler G, Sebastian M, Fernandez RS, Vick K, Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. *Br J Dermatol*. 2008;158(4):801-7.
76. Ramirez-Bosca A, Zapater P, Betlloch I, et al. Polypodium leucotomos extract in atopic dermatitis: a randomized, double-blind, placebo-controlled, multicenter trial. *Actas Dermosifiliogr*. 2012;103(7):599-607.
77. Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. *Br J Dermatol*. 2005;152(6):1282-9.
78. Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. *Lancet*. 2001;357(9273):2012-6.
79. Ricci G, Patrizi A, Specchia F, et al. Effect of house dust mite avoidance measures in children with atopic dermatitis. *Br J Dermatol*. 2000;143(2):379-84.
80. Rosenfeldt V, Benfeldt E, Nielsen SD, et al. Effect of probiotic *Lactobacillus* strains in children with atopic dermatitis. *J Allergy Clin Immunol*. 2003;111(2):389-95.
81. Ruer-Mulard M, Aberer W, Gunstone A, et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. *Pediatr Dermatol*. 2009;26(5):551-8.
82. Salavec M, Bučková H. First Experiences with 1% Pimecrolimus Cream Therapy in Prevention of Atopic Eczema Flares in Children. *Čes-slov Derm*. 2004;79(1):3-7.
83. Sanchez Caraballo JM, Cardona Villa R. Clinical and immunological changes of immunotherapy in patients with atopic dermatitis: randomized controlled trial. *ISRN Allergy*. 2012;2012:183983.
84. Schmitt J, Schakel K, Folster-Holst R, et al. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. *Br J Dermatol*. 2010;162(3):661-8.
85. Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. *J Allergy Clin Immunol*. 2011;128(2):353-9.
86. Schut C, Weik U, Tews N, Gieler U, Deinzer R, Kupfer J. Psychophysiological effects of stress management in patients with atopic dermatitis: a randomized controlled trial. *Acta Derm Venereol*. 2013;93(1):57-61.
87. Schuttelaar ML, Vermeulen KM, Drukker N, Coenraads PJ. A randomized controlled trial in children with eczema: nurse practitioner vs. dermatologist. *Br J Dermatol*. 2010;162(1):162-70.
88. Senapati S, Banerjee S, Gangopadhyay DN. Evening primrose oil is effective in atopic dermatitis: a randomized placebo-controlled trial. *Indian J Dermatol Venereol Leprol*. 2008;74(5):447-52.
89. Shibata R, Kimura M, Takahashi H, et al. Clinical effects of kestose, a prebiotic oligosaccharide, on the treatment of atopic dermatitis in infants. *Clin Exp Allergy*. 2009;39(9):1397-403.
90. Sigurgeirsson B, Ho V, Ferrandiz C, Andriano K, Grinienko A, Jimenez P. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. *J Eur Acad Dermatol Venereol*. 2008;22(11):1290-301.
91. Sistik D, Kelly R, Wickens K, Stanley T, Fitzharris P, Crane J. Is the effect of probiotics on atopic dermatitis confined to food sensitized children? *Clin Exp Allergy*. 2006;36(5):629-33.

92. Staab D, Diepgen TL, Fartasch M, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. *BMJ*. 2006;332(7547):933-8.
93. Stainer R, Matthews S, Arshad SH, et al. Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial. *Br J Dermatol*. 2005;152(2):334-41.
94. Svejgaard E, Larsen PO, Deleuran M, Ternowitz T, Roed-Petersen J, Nilsson J. Treatment of head and neck dermatitis comparing itraconazole 200 mg and 400 mg daily for 1 week with placebo. *J Eur Acad Dermatol Venereol*. 2004;18(4):445-9.
95. Takwale A, Tan E, Agarwal S, et al. Efficacy and tolerability of borage oil in adults and children with atopic eczema: randomised, double blind, placebo controlled, parallel group trial. *BMJ*. 2003;327(7428):1385.
96. Hattori K, Yamamoto A, Sasai M, et al. [Effects of administration of bifidobacteria on fecal microflora and clinical symptoms in infants with atopic dermatitis]. *Arerugi*. 2003;52(1):20-30.
97. Tanuichi S, Hattori K, Yamamoto A, et al. Administration of Bifidobacterium to Infants with Atopic Dermatitis: Changes in Fecal Microflora and Clinical Symptoms. *J Appl Res*. 2005;5(2):387-96.
98. Thaci D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. *Br J Dermatol*. 2008;159(6):1348-56.
99. Thomas KS, Dean T, O'Leary C, et al. A randomised controlled trial of ion-exchange water softeners for the treatment of eczema in children. *PLoS Med*. 2011;8(2):e1000395.
100. Thomas KS, Armstrong S, Avery A, et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. *BMJ*. 2002;324(7340):768.
101. Trookman NS, Rizer RL. Randomized Controlled Trial of Desonide Hydrogel 0.05% versus Desonide Ointment 0.05% in the Treatment of Mild-to-moderate Atopic Dermatitis. *J Clin Aesthet Dermatol*. 2011;4(11):34-8.
102. Tzaneva S, Kittler H, Holzer G, et al. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. *Br J Dermatol*. 2010;162(3):655-60.
103. van Os-Medendorp H, Koffijberg H, Eland-de Kok PC, et al. E-health in caring for patients with atopic dermatitis: a randomized controlled cost-effectiveness study of internet-guided monitoring and online self-management training. *Br J Dermatol*. 2012;166(5):1060-8.
104. van der Aa LB, Heymans HS, van Aalderen WM, et al. Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial. *Clin Exp Allergy*. 2010;40(5):795-804.
105. Viljanen M, Savilahti E, Haahtela T, et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. *Allergy*. 2005;60(4):494-500.
106. Vita D, Passalacqua G, Di Pasquale G, et al. Ass's milk in children with atopic dermatitis and cow's milk allergy: crossover comparison with goat's milk. *Pediatr Allergy Immunol*. 2007;18(7):594-8.
107. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. *Pediatrics*. 2002;110(1 Pt 1):e2.
108. Wang Y, B. M. The efficacy of de-escalation therapy on the treatment of chronic eczema. *Journal of Clinical Dermatology*. 2011;40(5):303-5.
109. Weston S, Halbert A, Richmond P, Prescott SL. Effects of probiotics on atopic dermatitis: a randomised controlled trial. *Arch Dis Child*. 2005;90(9):892-7.

110. Wiren K, Nohlgard C, Nyberg F, et al. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. *J Eur Acad Dermatol Venereol*. 2009;23(11):1267-72.
111. Wolff K, Fleming C, Hanifin J, et al. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. *Br J Dermatol*. 2005;152(6):1296-303.
112. Wollenberg A, Reitamo S, Girolomoni G, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. *Allergy*. 2008;63(7):742-50.
113. Woo SI, Kim JY, Lee YJ, Kim NS, Hahn YS. Effect of *Lactobacillus sakei* supplementation in children with atopic eczema-dermatitis syndrome. *Ann Allergy Asthma Immunol*. 2010;104(4):343-8.

